Lianne E. Rotin

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Targeting Bruton's tyrosine kinase (BTK) with the small molecule BTK inhibitor ibrutinib has significantly improved patient outcomes in several B-cell malignancies, with minimal toxicity. Given the reported expression and constitutive activation of BTK in acute myeloid leukemia (AML) cells, there has been recent interest in investigating the anti-AML(More)
  • 1